SHORT REPORT

Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice

S D Shorvon, R C Tallis, H K Wallace

OBJECTIVES: To determine the frequency of coprescription of antiepileptic drugs (AEDs) and drugs with proconvulsant potential and of coprescription of AEDs and low dose oral contraceptives.

METHODS: Using information from all 294 fully computerised general practices participating in the General Practice Research Database who entered complete data in 1995, persons were identified who had a prescription for an antiepileptic drug and who had a diagnosis of epilepsy or epileptic seizures in their medical records. Other medication was also recorded.

RESULTS: Of women with epilepsy aged 15–45, 16.7% were on an oral contraceptive pill and of 200 on both an enzyme inducing AED and an oral contraceptive, 56% were on formulations with an estrogen content less than 50 µg. This will be associated with increased risk of contraceptive failure and unwanted pregnancy. Over 10% of all AED prescriptions in adults were associated with simultaneous prescription of at least one drug with a potential proconvulsant effect.

CONCLUSIONS: Prescribers should be alert to the possibility of pharmacodynamic and pharmacokinetic interactions between AEDs and other medication. With the aging of the population of people with seizures, and the polypharmacy often associated with old age, the likelihood of adversely interacting drug combinations will increase.

METHODS

Population and case ascertainment

We used information from all 294 fully computerised general practices participating in the GPRD who entered complete data in 1995. Patients were included who had received a prescription for an antiepileptic drug during the study year and who had a diagnosis of epilepsy or epileptic seizures in their medical record. No attempt was made to separate incident from prevalent cases.

To identify the cases, the database was searched for:

1. All diagnostic codes which denote the various epilepsy syndromes and seizure types (and using various synonyms for epilepsy such as “seizure” etc).
2. Codes for all the different formulations of 11 AEDs: carbamazepine, clobazam; clonazepam, ethosuximide, gabapentin, lamotrigine, phenobarbital, phenytoin, sodium valproate, topiramate, and vigabatrin.

The age and sex distributions of the base populations were determined for the practices.

Diagnostic validity and reliability

The GPRD is a complex computerised system, set up primarily prospectively to track prescribing data. The participating general practices enter all drugs prescribed, a diagnosis/indication for each new prescription, the initial indication for any repeat prescriptions, and all instances of significant morbidity. The entries are recorded directly onto the computer system by the general practitioner in the surgery each time a patient is seen. The representativeness of the database is demonstrated by the almost identical age and sex distribution of the database population with that of the general population.

There have been extensive studies of the validity of the prescribing data, with good agreement between the GPRD and the Prescription Pricing Agency (PPA) prescribing data for CNS (and other) drugs, although AEDs have not been studied separately. The validity of the diagnostic data has also been shown over 90% diagnostic completeness. The aspects of care most reliably addressed by the GPRD are those related to medication, as the database was originally set up by the VAMP software company to record drug prescribing practice in adverse events. As drugs are a component of treatment for the vast majority of patients, epilepsy is a particularly suitable condition to investigate using the database.

Questions under investigation

Using the complete data set of 294 practices, we investigated for the year 1995:

ABBREVIATIONS: AEDs, antiepileptic drugs; GPRD, general practice research database; PPA, Prescription Pricing Agency
The use of proconvulsant drugs

In 1995, 16.7% (390/2341) of women with epilepsy aged 15–45 were taking the oral contraceptive pill, compared with a proportion of about 25% for the general population of women between these ages. Of 200 women taking both an enzyme inducing AED (carbamazepine, phenytoin, or phenobarbital) and an oral contraceptive, 56.5% were taking formulations with an estrogen content less than 50 µg and 43.5% were on a high estrogen content contraceptive pill. The efficacy of the pill is reduced by enzyme inducing AEDs and women who are on such AEDs should not be prescribed low dose estrogen preparations. This hazard of contraceptive failure and an unwanted pregnancy is entirely avoidable.

Prescribers should be alert for the possibility of pharmacodynamic and pharmacokinetic interaction between AEDs and other medication. In cases where patients’ seizures seem difficult to control, the possibility of coprescription of a proconvulsant drug should be entertained.

ACKNOWLEDGEMENTS

We thank the ONS for their help in providing data for this paper.

REFERENCES